Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist

Archives of Neurology

Volumn 65, Issue 10, 2008, Pages 1281-1283

  Klunk, William E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AUTOPSY; BRAIN BIOPSY; EDITORIAL; NEUROIMAGING; NORMOTENSIVE HYDROCEPHALUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANILINE COMPOUNDS; BIOPSY; BRAIN; COGNITION DISORDERS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EARLY DIAGNOSIS; FALSE NEGATIVE REACTIONS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SENILE PLAQUES; THIAZOLES;

EID: 54049112680     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.10.1281     Document Type: Editorial

References (23)

1. Engler H, Blomqvist G, Bergstrom M, et al. First human study with a benzothiazole amyloid-imaging agent in Alzheimer's disease and control subjects. Neurobiol Aging. 2002;23(suppl 1):S429.
2. Klunk WE, Lopresti BJ, Ikonomovic MD, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005;25(46):10598-10606.
3. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4′- methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003;23(6):2086-2092.
4. Bacskai BJ, Hickey GA, Skoch J, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A. 2003;100(21):12462-12467.
5. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319.
6. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351-357.
7. Thal DR, Rub U, Orantes M, Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791-1800.
8. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex. 1991;1(1):103-116.
9. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64(3):431-434.
10. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131(pt 6):1630-1645.
11. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of β-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol. 2008;65(10):1304-1309.
12. Spillantini MG, Goedert M, Jakes R, Klug A. Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease. Proc Natl Acad Sci U S A. 1990;87(10):3947-3951.
13. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129(pt 11):2856-2866.
14. Toyama H, Ye D, Ichise M, et al. PET imaging of brain with the beta-amyloid probe, [(11)C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2005;32(5):593-600.
15. Maeda J, Ji B, Irie T, et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci. 2007;27(41):10957-10968.
16. Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27(23):6174-6184.
17. Lippa CF, Saunders AM, Smith TW, et al. Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology. 1996;46(2):406-412.
18. Tomiyama T, Nagata T, Shimada H, et al. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol. 2008;63(3):377-387. doi:10.1002/ana.21321.
19. Ikonomovic MD, Abrahamson EE, Isanski BA, et al. X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease. Methods Enzymol. 2006;412:123-144.
20. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46(13):2740-2754.
21. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46(12):1959-1972.
22. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452.
23. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718-1725.